THERAPY DOSSIER · th-6d115b060393

Recombinant Prokineticin 2 (PROK2)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30391355 ↗2018Reported benefit

A new function for Prokineticin 2: Recruitment of SVZ-derived neuroblasts to the injured cortex in a mouse model of traumatic brain injury.

MouseTBIUnspecifiedC57BL/6MaleCortical injection

Model: Cortical traumatic brain injury in mice

Subventricular zone cells migrated to the injured cortex after traumatic brain injury, a PROK2 receptor antagonist reduced the number of subventricular zone cells reaching the injured cortex, and recombinant PROK2 injected into uninjured cortex attracted subventricular zone cells.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…